NCT01925183View on ClinicalTrials.gov

Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C

PHASE4CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Hepatitis C, ChronicHIV
Interventions
DRUG

Pegylated interferon alpha-2a

180mcg once weekly; subcutaneous injection

DRUG

Ribavirin

600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients \<75kg; orally

DRUG

Boceprevir

800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally

Trial Locations (1)

1090

Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna

All Listed Sponsors
collaborator

Medical University of Vienna

OTHER

lead

Markus Peck-Radosavljevic

OTHER

NCT01925183 - Individualized Triple-therapy Using Boceprevir in HIV-positive Patients With Hepatitis C | Biotech Hunter | Biotech Hunter